BRCA2 and neoplasm: Similar results were observed in BRCA2 mutant tumor lines CAPAN1 and PEO1, which showed increased U-ssDNA and pRPA32 co-staining compared to their isogenic BRCA2-revertant counterparts C2-12 and PEOC4, respectively (Supplementary Fig. 2b, c).